MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Pomdoctor Limited (POM) Stock Down -9.26% Today?

Why Is Pomdoctor Limited (POM) Stock Down -9.26% Today?

Key Takeaways

  • POM fell 9.26% in early trading, slipping $0.15 to $1.47 from the prior session's close of $1.62, with the move occurring in the opening minutes of the regular session.
  • No verified company-specific news, filing, or analyst action explains the decline; the session's selling appears to be a continuation of the stock's persistent post-restructuring downtrend.
  • Secondary factors include unresolved Nasdaq market-value listing deficiencies disclosed earlier in November and a still-pending securities class action over 2025 trading activity.
  • The broader tape was risk-off: major indices opened lower as Treasury yields held near 5.15% and investors positioned defensively ahead of a key semiconductor earnings report.
  • News Significance Score: 6/100 - No verified news and a price move smaller than the stock's own typical daily swing.
  • Traders are watching whether the shares hold above the $1.40 area, whether the $1.00 Nasdaq bid-price threshold comes back into play, and the timing of the next earnings release.
  • Investors can review detailed Price Targets, Earnings history, and Forecast pages for deeper context on the name.
  • Explore Trending AI Robots to see which automated strategies are currently performing best across thousands of tickers.

What Happened to POM Shares Today

Shares of Pomdoctor Limited (POM), a Guangzhou-based digital healthcare company that operates an internet-hospital platform and a pharmaceutical supply chain business in China, moved sharply lower in Tuesday's opening session. The stock was trading at $1.47, down $0.15 or 9.26%, compared with the prior completed session's close of $1.62. The direction was decisively negative, and the decline unfolded within the first minutes of the regular session rather than in pre-market trading.

No verified company announcement, regulatory filing, analyst rating change, or news-wire report was published ahead of the move that would account for a decline of this size.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found to explain the drop. The company's most recent public disclosures remain the November 6 confirmation that it regained compliance with Nasdaq's $1.00 minimum bid price requirement and the November 2 notices regarding deficiencies in the market value of listed securities and market value of publicly held shares, for which the company has until April 26, 2027 to regain compliance. Neither item was new to Tuesday's session.

The session's action is most consistent with the trading profile of a thinly traded micro-cap that has repeatedly repriced by double digits without news. Over the prior 69 completed sessions, POM moved by an average of roughly 10.2% per session in absolute terms, and 27 of those sessions produced swings equal to or larger than today's 9.26%. That history - including a 54.7% single-session collapse in late October following a listing-structure restructuring - points to speculative flows and a shallow order book rather than a fundamental shock.

Today's decline also erases most of the recovery that began after the mid-November bounce, taking the shares back toward the $1.40 region that capped the October selloff's floor. A market capitalization of roughly $53 million on about 36 million shares outstanding leaves little cushion for order flow of even modest size.

Market Context and Trading Activity

Activity in the name has thinned considerably since the October volatility. The stock traded 14,480 shares on November 16 and just 3,310 shares on November 13, well below the three-month average volume of roughly 2 million shares, which was inflated by the October listing transition and related selling. Light participation amplifies percentage moves, and a decline of this magnitude can occur on relatively small volume.

Broader markets offered no support. Major U.S. indices opened lower on renewed inflation and interest-rate concerns, with the benchmark 10-year Treasury yield near 5.15% keeping pressure on long-duration and speculative equities. Investor attention was fixed on an after-close semiconductor earnings report and a large upcoming artificial-intelligence IPO, drawing capital away from small-cap and micro-cap names. Small-cap benchmarks were softer at the open, and China-based U.S.-listed healthcare issuers were mixed rather than uniformly weaker, indicating the move was company- and float-specific rather than sector-driven.

Technically, the shares sit slightly above the 50-day moving average near $1.13 and far below the 200-day average near $2.75, a structure consistent with a long downtrend interrupted by sharp, short-lived rallies.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, rare price move. On that scale, this session rates 6 out of 100.

No verified fundamental news was identified, so the catalyst component is negligible relative to a company of this size. The price component is equally muted: today's 9.26% decline is smaller than the stock's typical daily move of about 10.2% over the past 69 sessions, and comparable or larger swings occurred 27 times in that window. With neither a strong news driver nor an unusual move, the two factors combine into a low score.

What Comes Next for POM

The next scheduled catalyst is the company's next earnings release, currently estimated for late November, which will be the first report since the October move to direct Nasdaq listing of Class A ordinary shares and the associated consolidation. Investors will focus on revenue growth in the internet-hospital and pharmaceutical supply chain segments, cash position, and progress on the company's stated shift toward AI-enabled and predictive healthcare services. Separate from the price action, Pomdoctor continues to operate under a 180-day cure period to rebuild its market value of listed securities above $50 million and its publicly held share value above $15 million by April 2027, and it faces a pending securities class action in the Southern District of New York concerning 2025 trading in its securities. Further equity issuance risk remains given negative stockholders' equity and a history of dilution. Any renewed slide toward $1.00 would re-open listing-compliance questions.

Trending AI Robots

Tickeron maintains a curated Trending AI Robots page that surfaces only the strongest performing automated strategies under current market conditions, drawn from a library of hundreds of bots covering thousands of tickers. Bots differ widely by strategy logic, holding timeframe, risk profile, performance metrics, and the specific symbols they trade, so results vary substantially across market regimes. For volatile, thin-float names such as this one, reviewing which bots are actually working right now can be a useful starting point. Visit the page to see the current leaders.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: POM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for POM turns positive, indicating new upward trend

POM saw its Momentum Indicator move above the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator turned positive. In 18 of the 20 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where POM's RSI Indicator exited the oversold zone, 5 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 8 of 10 cases where POM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for POM just turned positive on November 06, 2026. Looking at past instances where POM's MACD turned positive, the stock continued to rise in 6 of 7 cases over the following month. The odds of a continued upward trend are 86%.

POM moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for POM crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +7.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where POM advanced for three days, in 57 of 64 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

POM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where POM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for POM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: POM's P/B Ratio (0.000) is slightly lower than the industry average of (1.378). P/E Ratio (0.000) is within average values for comparable stocks, (-2.174). POM's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.947). Dividend Yield (0.000) settles around the average of (0.246) among similar stocks. P/S Ratio (0.043) is also within normal values, averaging (2.504).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. POM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.

Industry description

The drugstore chains industry includes stores that sell medicines (both prescription and non-prescription), health, beauty and personal care products. Over time, many pharmacy retail chains have launched their own pharmacy benefits management services. Since demand for medical products is typically less sensitive to economic cycles, drugstore retail chains industry could be largely considered as non-cyclical. CVS Health Corporation, Walgreens Boots Alliance Inc. and Rite Aid Corporation are some of the biggest operators in this industry.

Market Cap

The average market capitalization across the Drugstore Chains Industry is 82.05M. The market cap for tickers in the group ranges from 36.55K to 14.27B. JDHIF holds the highest valuation in this group at 14.27B. The lowest valued company is PNPL at 36.55K.

High and low price notable news

The average weekly price growth across all stocks in the Drugstore Chains Industry was -10%. For the same Industry, the average monthly price growth was -19%, and the average quarterly price growth was -53%. POM experienced the highest price growth at -3%, while SCNX experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Drugstore Chains Industry was 24%. For the same stocks of the Industry, the average monthly volume growth was 100% and the average quarterly volume growth was 10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 77
Price Growth Rating: 79
SMR Rating: 82
Profit Risk Rating: 100
Seasonality Score: 0 (-100 ... +100)
AI Screener 3